OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gene Therapy in Hemophilia: Recent Advances
E. Carlos Rodríguez‐Merchán, Juan A. De Pablo-Moreno, Antonio Liras
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7647-7647
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V
Juan A. De Pablo-Moreno, Luis Javier Serrano, Luis Revuelta, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8283-8283
Open Access | Times Cited: 51

The Molecular Basis of FIX Deficiency in Hemophilia B
Guomin Shen, Meng Gao, Qing Cao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2762-2762
Open Access | Times Cited: 32

Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery
Eloïse Hudry, Fumiaki Aihara, Emily K. Meseck, et al.
Molecular Therapy (2023) Vol. 31, Iss. 10, pp. 2999-3014
Open Access | Times Cited: 20

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment
Rubhan Chandran, Eusni Rahayu Mohd Tohit, Johnson Stanslas, et al.
Seminars in Thrombosis and Hemostasis (2024) Vol. 50, Iss. 05, pp. 695-713
Closed Access | Times Cited: 8

Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases
Carleigh Sussman, Rachel A. Liberatore, M. Dróżdż
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 535-535
Open Access | Times Cited: 6

New directions to develop therapies for people with hemophilia
Pooja Gogia, Michael D. Tarantino, Wolfgang Schramm, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 6, pp. 417-433
Open Access | Times Cited: 12

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia
Duc Quang Tran, Craig C Benson, Judith A. Boice, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. sup1, pp. 19-37
Open Access | Times Cited: 12

Advancements in the diagnosis and management of haemophilia from traditional therapies to gene editing: a narrative review
Dunya Yunus Alsomali, Saja Fawzi Alzanbaqi, Assal Badr Aldeen Hobani, et al.
International Journal of Community Medicine and Public Health (2025) Vol. 12, Iss. 3, pp. 1499-1502
Open Access

CRISPR/Cas9 gene editing for treating gene and protein disorders
Chukwuebuka Emmanuel Umeyor, Preeya Negi, R. Agarwal, et al.
Elsevier eBooks (2025), pp. 519-553
Closed Access

The Arrival of Gene Therapy for Patients with Hemophilia A
Giancarlo Castaman, Giovanni Di Minno, Raimondo De Cristofaro, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10228-10228
Open Access | Times Cited: 18

Operationalising a Haemophilia Gene Editing Lexicon for Practical Use
William McKeown, Cédric Hermans, Carmen Unzu, et al.
Haemophilia (2025)
Closed Access

Lymphoblastoid and Jurkat cell lines are useful surrogate in developing a CRISPR-Cas9 method to correct leukocyte adhesion deficiency genomic defect
A. Ramadan, Noureddine Ben Khalaf, Khaled Trabelsi, et al.
Frontiers in Bioengineering and Biotechnology (2025) Vol. 13
Open Access

Global trends in hemophilic arthropathy research: a bibliometric and visualization analysis
Zengtao Wei, Linlin Ou, Sheng Chai, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access

Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyễn Phương Thảo, Thuy-vi Nguyen, Soyeun Park
Journal of Pharmaceutical Investigation (2025)
Closed Access

Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies
Ivano Condò
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6525-6525
Open Access | Times Cited: 14

Correction of F8 intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR/Cas9 mediated gene editing
Zhiqing Hu, Yong Wu, Rou Xiao, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 8

Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated
Ming Kei Lee, Sama Seyedmousavi, Sylvain Auvity, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2

Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas)
Juan A. De Pablo-Moreno, Andrea Miguel-Batuecas, E. Carlos Rodríguez‐Merchán, et al.
Thrombosis Research (2023) Vol. 231, pp. 99-111
Open Access | Times Cited: 6

High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies
Sara Bernal, Irene Peláez, Laura Alías, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9705-9705
Open Access | Times Cited: 12

The current role of artificial intelligence in hemophilia
E. Carlos Rodríguez‐Merchán
Expert Review of Hematology (2022) Vol. 15, Iss. 10, pp. 927-931
Closed Access | Times Cited: 7

Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
Samantha Pasca, Ezio Zanon
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3109-3116
Open Access | Times Cited: 7

C and G are frequently mutated into T and A in coding regions of human genes
Yong Wang, Keping Chen
Molecular Genetics and Genomics (2024) Vol. 299, Iss. 1
Closed Access | Times Cited: 1

Patient Perspective on Disease Burden and Gene Therapy for Hemophilia A and B: The “Haemvolution for Patients” Italian Survey
Maria Francesca Mansueto, Sarah Bigi, Marco Follino, et al.
Seminars in Thrombosis and Hemostasis (2024)
Closed Access | Times Cited: 1

Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review
Łukasz Mazurkiewicz, Krystian Czernikiewicz, Joanna Rupa‐Matysek, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 10, pp. 933-942
Closed Access | Times Cited: 6

Delivery of gene therapy in haemophilia treatment centres in the United States: Practical aspects of preparedness and implementation
Steven W. Pipe, Kayla Douglas, Nina Hwang, et al.
Haemophilia (2023) Vol. 29, Iss. 6, pp. 1430-1441
Open Access | Times Cited: 3

Page 1 - Next Page

Scroll to top